TNFRSF17 Human, Sf9
Sf9, Baculovirus cells.
BCMA, CD269, Tumor Necrosis Factor Receptor Superfamily Member 17, BCM, TNFRSF17, B-cell maturation protein, CD269 antigen
Greater than 95.0% as determined by SDS-PAGE.
Description
TNFRSF17 Human Recombinant produced in Baculovirus is a single glycosylated polypeptide chain containing 296 amino acids (1-54 aa) and having a molecular mass of 33.1Da.
TNFRSF17 is fused to a 242 amino acid hIgG-His-Tag at C-terminus and purified by proprietary chromatographic techniques.
Product Specs
B-Cell Maturation Antigen, also known as TNFRSF17 or tumor necrosis factor receptor superfamily member 17, belongs to the TNF receptor protein family. This protein serves as a receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL, promoting B-cell survival. TNFRSF17 plays a critical role in regulating humoral immunity and is involved in activating NF-kappa-B and JNK signaling pathways.
Recombinant human TNFRSF17 protein is produced in Baculovirus (Sf9 insect cells) as a single glycosylated polypeptide chain. It consists of 296 amino acids, including amino acids 1-54, and has a molecular mass of 33.1 kDa. TNFRSF17 is fused to a 242 amino acid hIgG-His-Tag at the C-terminus and is purified using proprietary chromatographic techniques.
The TNFRSF17 protein is supplied at a concentration of 0.5 mg/ml in a solution containing 10% glycerol and Phosphate-Buffered Saline (pH 7.4).
For short-term storage (2-4 weeks), the product can be stored at 4°C. For long-term storage, it is recommended to store the protein at -20°C. To further enhance stability during long-term storage, the addition of a carrier protein (0.1% HSA or BSA) is advisable. It's important to avoid repeated freeze-thaw cycles to maintain protein integrity.
The purity of TNFRSF17 is determined to be greater than 95.0% by SDS-PAGE analysis.
BCMA, CD269, Tumor Necrosis Factor Receptor Superfamily Member 17, BCM, TNFRSF17, B-cell maturation protein, CD269 antigen
Sf9, Baculovirus cells.
ADPMLQMAGQ CSQNEYFDSL LHACIPCQLR CSSNTPPLTC QRYCNASVTN SVKGTNALEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK HHHHHH
Product Science Overview
BCMA is part of the TNF receptor protein family and is primarily expressed in mature B lymphocytes . It specifically binds to B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are essential for B-cell survival and proliferation . The interaction between BCMA and its ligands leads to the activation of NF-kappaB and MAPK8/JNK signaling pathways, promoting cell survival and immune response .
The recombinant form of BCMA, produced in Sf9 cells (a cell line derived from the fall armyworm Spodoptera frugiperda), is a single glycosylated polypeptide chain containing 296 amino acids . This recombinant protein is fused to a 242 amino acid hIgG-His-Tag at the C-terminus and is purified using proprietary chromatographic techniques . The recombinant BCMA is used in various research applications, including studies on B-cell development, autoimmune diseases, and cancer .
BCMA is a critical target in the treatment of multiple myeloma, a type of blood cancer. Elevated levels of soluble BCMA (sBCMA) are found in the serum of patients with multiple myeloma, making it a valuable biomarker for disease progression and treatment response . Additionally, BCMA-targeted therapies, such as CAR-T cell therapy and antibody-drug conjugates, have shown promising results in clinical trials for multiple myeloma .
